Browse by author
Lookup NU author(s): Dr Harish Datta
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
FK506 is a commonly used immunosuppressant that mediates its action by exclusively interacting with the cytosolic immunophilin, FK506 binding protein 12 (FKBP12). Although FK506-induced acute osteoporosis is now well recognised, its precise mode of action in osteoblasts remains unclear. Therefore, in the present study we characterised FKBP12 in osteoblasts and investigated the role of FK506 in modulating osteoblast-specific transcription factors, core-binding factor α1 (Cbfa1) and osterix gene expression in ROS 17/2.8 cells. RT-PCR, immunolocalisation and Western blotting studies were employed to identify and characterise FKBP12 in rat primary osteoblasts and osteoblast-like osteosarcoma ROS 17/2.8 cells. Western blotting extracts of these cells revealed the 12 kDa and hitherto unreported 10 kDa FKBP isoform that were immunolocalised predominantly to the cytosol. The transient exposure of ROS 17/2.8 cells to H2O2 (100 μM) was found to elevate FKBP12 mRNA after 10 min and protein expression after 24 h. Both PTH (10-9 M) and 1,25 (OH)2D3 (Vitamin D3) (10-7 M) suppressed FKBP12 protein expression. FK506 in the therapeutic range (25 nmol/L) suppressed expression of Cbfa1 and osterix mRNA. The inhibition of Cbfa1 isoforms II/III expression was evident at 30 min and the extent of inhibition was sustained at 6 h. Osterix inhibition was also seen after 30 min, however, it became maximal after 6 h. The dose-dependant inhibition of osterix in these cells, carried out using 1.25, 12.5 and 125 nmol/L of FK506 was maximal at 1.25 nmol/L. Cbfa1 isoforms II/III were also maximally inhibited at 1.25 nmol/L; interestingly, the inhibition became less marked at higher concentrations of FK506. Similar dose of FK506 was found to inhibit ROS 17/2.8 cell proliferation; the inhibitory effect however was greater in insulin-stimulated cells. The results of this study suggest that immunosuppressant-induced osteoporosis, which is known to involve accelerated bone resorption by increase in osteoclastogenesis, may in fact also be accentuated by the inhibition of osteoblast differentiation and function. © 2004 Elsevier Inc. All rights reserved.
Author(s): Varanasi SS, Datta HK
Publication type: Article
Publication status: Published
Journal: Bone
Year: 2005
Volume: 36
Issue: 2
Pages: 243-253
Print publication date: 01/02/2005
ISSN (print): 8756-3282
ISSN (electronic):
Publisher: Elsevier
URL: http://dx.doi.org/10.1016/j.bone.2004.09.021
DOI: 10.1016/j.bone.2004.09.021
PubMed id: 15780950
Altmetrics provided by Altmetric
